Jefferies initiated coverage of Apollo Medical with a Buy rating and $50 price target. The firm says Apollo is an “under-followed company” with a long history of execution in value-based care that has made recent strides to modernize the business. The company has a favorable mix that should stabilize results relative to peers in the near-term and its 20% EBITDA growth outlook to fiscal 2025 is compelling, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMEH:
- AMEH Earnings this Week: How Will it Perform?
- Apollo Medical to change name to Astrana Health, effective February 26
- Apollo Medical upgraded to Buy from Neutral at BofA
- Apollo Medical Holdings Announces Strategic Acquisitions
- Apollo Medical Holdings Issues 631K Shares in Private Sale
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue